These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 16709987)

  • 41. Reinventing an industry.
    Mandavilli A
    Nature; 2007 Jan; 445(7124):138-9. PubMed ID: 17215817
    [No Abstract]   [Full Text] [Related]  

  • 42. Supreme Court rules against drug patent "evergreening".
    Kondro W
    CMAJ; 2006 Dec; 175(12):1508-9. PubMed ID: 17146081
    [No Abstract]   [Full Text] [Related]  

  • 43. Global patent police block cost-reduction efforts.
    Kasper T
    GMHC Treat Issues; 1999 Mar; 13(3):1-2. PubMed ID: 11366201
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Balancing pills and patents: intellectual property and the HIV/AIDS crisis.
    Nderitu T
    E Law; 2001 Sep; 8(3):E5. PubMed ID: 16903022
    [No Abstract]   [Full Text] [Related]  

  • 45. Generic Truvada approved.
    AIDS Patient Care STDS; 2009 May; 23(5):395. PubMed ID: 19422066
    [No Abstract]   [Full Text] [Related]  

  • 46. TRIPS: generic irony.
    Howarth GR
    Br J Gen Pract; 2002 Jan; 52(474):57. PubMed ID: 11791819
    [No Abstract]   [Full Text] [Related]  

  • 47. Generic drug companies are the winners.
    Voth AJ
    CMAJ; 1991 Nov; 145(9):1081. PubMed ID: 1751924
    [No Abstract]   [Full Text] [Related]  

  • 48. Brazil's AIDS controversy: antiretroviral drugs, breaking patents, and compulsory licensing.
    Marques UR; Guimarães VS; Sternberg C
    Food Drug Law J; 2005; 60(3):471-7. PubMed ID: 16304752
    [No Abstract]   [Full Text] [Related]  

  • 49. Brazil: Gilead cuts tenofovir price in half.
    AIDS Treat News; 2006; (418):8. PubMed ID: 16886262
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Generic drugs go to market. Effective, safe and less expensive.
    Mayo Clin Health Lett; 2006 Sep; 24(9):4-5. PubMed ID: 17139760
    [No Abstract]   [Full Text] [Related]  

  • 51. MSF challenges Novartis's action over Indian patent for imatinib.
    Mudur G
    BMJ; 2007 Jan; 334(7586):172. PubMed ID: 17255582
    [No Abstract]   [Full Text] [Related]  

  • 52. Canada decides to lead the way in exempting AIDS drugs from patent laws.
    Spurgeon D
    BMJ; 2003 Oct; 327(7419):832. PubMed ID: 14551093
    [No Abstract]   [Full Text] [Related]  

  • 53. Final hearings begin in epic legal battle over Novartis drug in India.
    Mudur G
    BMJ; 2012 Sep; 345():e6257. PubMed ID: 22991008
    [No Abstract]   [Full Text] [Related]  

  • 54. Generics battle brand names over mortality of drug patents.
    Betz R
    J Healthc Resour Manag; 1995 Jul; 13(7):35-7. PubMed ID: 10144008
    [No Abstract]   [Full Text] [Related]  

  • 55. A generic problem.
    Hanauer SB
    Nat Clin Pract Gastroenterol Hepatol; 2006 Dec; 3(12):649. PubMed ID: 17130869
    [No Abstract]   [Full Text] [Related]  

  • 56. Changes to India's patent law: unaffordable drugs may discourage diagnosing HIV and increase transmission.
    Joshi SB
    BMJ; 2005 Apr; 330(7498):1025. PubMed ID: 15860836
    [No Abstract]   [Full Text] [Related]  

  • 57. Patent laws high on the agenda at WTO.
    Frankish H
    Lancet; 2001 Nov; 358(9294):1706. PubMed ID: 11728560
    [No Abstract]   [Full Text] [Related]  

  • 58. Brazil and India file complaint against EU over seizure of generic drugs.
    Zarocostas J
    BMJ; 2010 May; 340():c2672. PubMed ID: 20483945
    [No Abstract]   [Full Text] [Related]  

  • 59. India: Court upholds patent law denying patents for slightly modified versions of existing drugs.
    Swamy M
    HIV AIDS Policy Law Rev; 2007 Dec; 12(2-3):50-1. PubMed ID: 18459215
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Patent watch: Indian patent office rejects HIV drug formulation patent.
    Harrison C
    Nat Rev Drug Discov; 2011 Feb; 10(2):88. PubMed ID: 21283096
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.